NUZ

5.26%

20.0¢ neurizon therapeutics limited

Paradigm Shift, page-13

First 13 Last

Share
Profile

Follow
illdrink2that

1,432 Posts.

1027

05/07/20

16:03

Post #: 45653374
Share

Originally posted by PickEm: ↑

Adaptive Cell Therapy

When viewed in relation to targeted cancer drugs, part of the idea is that you're not pushing cancer so hard that it evolves quickly past the block you've put in.

Professor Maley is saying that as cancer evolves within a lifetime, to maximise the active longevity of patients, the dose and timing of treatments must be guided by evolutionary principles - which we understand fairly well. Even the immune system doesn't try to completely eradicate invaders, but to knock them down to harmless levels. It's a cost benefit balance.

The Moffitt Cancer Centre in the US ran an adaptive therapies metastatic prostate trial which is now complete and being written-up. The released results will not disappoint because the interim results were so spectacular. The 3 other trials are underway; ovarian, melanoma and thyroid. The Moffitt Cancer Centre is a rather special place and I get the feeling of restrained excitement from them.

There is the possibility that monepantel is ideally suited to this approach - close to non-toxic at lower doses, sometimes tumour reducing but more tumour holding over time. A dramatic reduction in tumour size is currently considered a good thing, but adaptive therapy says no. Just holding tumour growth will be far more beneficial to extending long term survival.

And then monepantels latest gift which has gone largely unnoticed.Monepantel has a biphasic nature which might be dose forgiving. If efficacy is assumed to be its tumour reducing performance, it gives a "U" with optimal dose efficacy at the bottom of the U. If halting growth is best efficacy, the biphasic "U" turns more into a "W" ... we have possibly dosed slightly high but maybe near enough to the second dip - as hinted by the 4 dogs in 28 day stasis - around a point where adaptive control might work.

I think little PharmAust has a big shot. Can't see any other junior pharma on the ASX playing with such upside, and that ignores the virus. Could be one hell of a ride but all imo.

Either way, the coming weeks are guaranteed to be interesting.
Well that was an effort and hope my fellow holders find some of it interesting. I'm all worded out ... siesta time ...

Good luck to all holders ... and just for Cashie .. !sredloh lla ot kcul dooG

Expand

Thank you for all the effort in sharing that PickEm. I'm gonna have to go back through all the posts again to get my head around some of those bits though. I'm glad your sentiment is HOLD. I owe you GAs but have run out again for the day. Really excellent posts coming through this weekend!

PAA Price at posting: 24.0¢ Sentiment: Hold Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

First 13 Last

Add NUZ (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change 0.010(5.26%)		Mkt cap ! $98.34M

Open	High	Low	Value	Volume
20.0¢	20.5¢	19.5¢	$86.20K	429.7K

Buyers (Bids)

No.	Vol.	Price($)
3	67508	19.5¢

Sellers (Offers)

Price($)	Vol.	No.
20.0¢	36444	3

View Market Depth

No.	Vol.	Price($)
3	67508	0.195
7	258826	0.190
12	723520	0.185
6	377800	0.180
5	151797	0.175

Price($)	Vol.	No.
0.200	36444	3
0.205	21529	1
0.210	107676	2
0.215	154400	2
0.220	190000	3

Last trade - 16.10pm 15/11/2024 (20 minute delay)

NUZ (ASX) Chart

Paradigm Shift, page-13

Banshee's historic trenches prove rich in antimony and gold for GDM

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Cyclone signs MOU with Vale for development of Iron Bear play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Paradigm Shift, page-13

Top Stories

Banshee's historic trenches prove rich in antimony and gold for GDM

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Cyclone signs MOU with Vale for development of Iron Bear play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News